Northstar Group Inc. Trims Stock Position in Stryker Corporation $SYK

Northstar Group Inc. lowered its position in shares of Stryker Corporation (NYSE:SYK) by 0.6% in the 2nd quarter, Holdings Channel.com reports. The fund owned 6,286 shares of the medical technology company’s stock after selling 39 shares during the period. Northstar Group Inc.’s holdings in Stryker were worth $2,487,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of SYK. Goodman Advisory Group LLC purchased a new position in Stryker in the 1st quarter worth approximately $32,000. City Holding Co. grew its stake in Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock worth $33,000 after buying an additional 74 shares in the last quarter. Ridgewood Investments LLC grew its stake in Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after buying an additional 30 shares in the last quarter. Ransom Advisory Ltd purchased a new position in Stryker in the 1st quarter worth approximately $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new position in Stryker in the 1st quarter worth approximately $40,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 1.5%

Shares of SYK opened at $364.07 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The firm has a market cap of $139.19 billion, a price-to-earnings ratio of 48.22, a PEG ratio of 2.66 and a beta of 0.95. The firm has a 50 day moving average price of $384.08 and a 200-day moving average price of $379.01.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $5.92 billion. During the same quarter last year, the business earned $2.81 earnings per share. The business’s revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is currently 44.50%.

Analyst Ratings Changes

A number of equities analysts have commented on SYK shares. BTIG Research reissued a “buy” rating on shares of Stryker in a research note on Monday, July 14th. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a research note on Friday, September 26th. Wells Fargo & Company boosted their price target on shares of Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. Rothschild & Co Redburn started coverage on shares of Stryker in a research note on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target on the stock. Finally, Rothschild Redb upgraded shares of Stryker to a “hold” rating in a report on Thursday, September 18th. Fourteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $430.33.

Insider Activity at Stryker

In other news, insider Viju Menon sold 500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This represents a 5.84% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.